1. Scrip
  2. >>Business
  3. >>Financing

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016

 
• By Mandy Jackson

Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.

Biopharma In Perspective 2016-2017

Money flowed to startups around the world in 2016 at a pace similar to 2015, providing for a steady stream of new companies to fill an important part of the biopharma ecosystem, and global venture capital is expected to keep pouring into drug discovery and development in 2017 as well.

Data gathered by Scrip and Informa Pharma Intelligence’s Strategic Transactions database show that 148 Series A and seed rounds totaling $3.5bn were completed in the US, Europe and Asia through Dec. 15, 2016 versus 156 Series A and seed rounds totaling $4bn for all 12 months of 2015

More from Financing

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

More from Business